The concern of generic challenges has consistently loomed over copyright’s iconic drug, Viagra, sparking questions about the future of related pharmaceutical investments. While early years saw impressive returns, the patent lapse has allowed the path for less expensive copies, potentially diminishing earnings and presenting a genuine danger for s